Global Healthcare And Aging Trends Will Unleash Market Opportunity

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Apr 25

Updated

11 Dec 25

Views

309

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

25.0%

7D

0.2%

Loading

1Y

25.0%

7D

0.2%

You can edit this narrative until Dec 12 12:10 AM. Then, changes will post as Updates.

Author's Valuation

US$11.650.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

ARDX: Upcoming Leadership Transition Will Support Long Term Earnings Upside

Analysts have modestly reiterated their confidence in Ardelyx, keeping the price target essentially unchanged at approximately 11.60 dollars per share. Minor adjustments to the discount rate and valuation inputs did not materially alter their long term earnings and growth outlook for the company.

Shared on 26 Nov 25

Fair value Decreased 1.09%

ARDX: Commercial Execution Will Drive Shares Higher Under New Leadership

Ardelyx’s analyst price target has been raised from $12 to $14, a $2 increase. Analysts cite stronger commercial execution and discounted valuation under new management as key drivers for the higher outlook.

Shared on 07 Nov 25

Fair value Increased 3.20%

ARDX: Ongoing Commercial Execution Will Unlock Upside From Discounted Levels

Analysts have raised Ardelyx’s fair value estimate from $11.36 to $11.73, citing stronger commercial execution, increased revenue growth potential, and a more favorable profit margin outlook. Analyst Commentary Recent coverage initiations have highlighted key perspectives among market observers evaluating Ardelyx’s trajectory and valuation.

Shared on 01 May 25

Fair value Increased 4.17%

AnalystConsensusTarget Fair Value

US$11.6

50.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

19.74%

Biotech revenue growth rate

8.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.30%

Calculation

US$243.13m

Earnings '28

x

15.16x

PE Ratio '28

=

US$3.69b

Market Cap '28

US$3.69b

Market Cap '28

/

257.37m

No. shares '28

=

US$14.32

Share Price '28

US$14.32 Share Price '28

Discounted to 2025 @ 7.33% p.a.

=

US$11.58

Fair Value '25